Untitled

[veyeteam]

3 Top ASX Tech Shares Under $10 With Strong Financials and Growth Guidance | Veye

These companies are top tech companies trading under $10, supported by financial performance and upgraded management guidance.

These companies are top tech companies trading under $10, supported by financial performance and upgraded management guidance.

Hansen Technologies Limited (ASX: HSN)

is one of the top tech companies listed on the ASX, with a market capitalisation of $897.87M and a partially franked dividend yield of 2.28%.

HSN had announced on 18 Feb 2026 its half-yearly results of FY26, ending in December 2025. Operating revenue is up by 7.5% YoY to $191.0M. Segment-wise, communication & media revenue increased by 13.5% to $82.3M, and energy & utilities revenue is up 3% YoY to $108.7M.

[veyeteam]

3 ASX Gold Stocks Delivering Record Production and Strong Cash Flow: GMD, EVN, RMS | Veye

Genesis Minerals, Evolution Mining and Ramelius Resources offer investors exposure to Australia’s gold sector, backed by strong production a

[veyeteam]

ASX Market Movers: FleetPartners, Mastermyne & Sunrise Energy Deliver Key Updates | Veye

The top three ASX stocks are trading near their 52-week high, supported by strong performance, new business acquisition and government backi

FleetPartners Group Limited (ASX: FPR)

is one of the top financial companies on the ASX, currently trading near its 52-week high with a market capitalisation of $833.16M and a fully franked dividend yield of 6.54%.

FPR has announced, on 10 August 2026, a response to SG Fleet NBIO and receipt of NBIO from Element. FPR, after careful consideration and consultation with its professional advisor, the FleetPartners Board, has rejected the SG Proposal for 100% acquisition of shares in FPR on the basis that the proposal undervalues the company and is not in the best interest of shareholders. The board of FPR is quite confident in the company’s strategy, market position and outlook and believes the FPR’s long-term value and prospects are not aligned with SG Fleet.

[veyeteam]

Top 3 Losing ASX Stocks Today: Life360, Amotiv & Starpharma Under Pressure | Veye

These are the top three losing ASX stocks, led by weakened results, funding issues and lackluster growth.

[veyeteam]

3 Top ASX Fintech Stocks to Watch: Block, Zip Co and HUB24 Show Strong Growth | Veye

Top fintech stocks worth watching, led by high growth, strong results, and improved management guidance.

[veyeteam]

2 ASX Healthcare Stocks to Watch: Neuren and CLINUVEL Make Key Pipeline Advances | Veye

NEU and CUV latest statements illustrate further advancements within their respective pipeline projects and other areas of operations, as we

[veyeteam]

2 ASX Healthcare Stocks to Watch: Neuren and CLINUVEL Make Key Pipeline Advances | Veye

NEU and CUV latest statements illustrate further advancements within their respective pipeline projects and other areas of operations, as we

Neuren Pharmaceuticals Limited (ASX: NEU)

on 29 June 2026, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use had recommended approval of DAYBU (trofinetide) in the European Union after a re-examination. The treatment is for neurobehavioral symptoms of Rett syndrome in adults and children aged five years and older. If approved, it would be the first treatment for this indication in the EU.